首页> 外文期刊>Journal of Microbiology, Biotechnology and Food Sciences >IMPLICATIONS OF ANTIBIOTIC RESISTANCES PRODUCED BY PHENOTHIAZINES IN Mycobacterium tuberculosis
【24h】

IMPLICATIONS OF ANTIBIOTIC RESISTANCES PRODUCED BY PHENOTHIAZINES IN Mycobacterium tuberculosis

机译:吩噻嗪类抗生素在结核分枝杆菌中产生的抗药性

获取原文
           

摘要

Several chemotherapeutic agents applied to human beings for past few decades for different ailments, have been found to possess potent antitubercular activity. Two such agents, methdilazine (Md) and promethazine (Pz) were used to select mycobacterial mutants resistant to themselves at different levels and tested to determine if such mutants simultaneously developed cross-resistance to known antitubercular drugs. Mutants were produced by application of a heavy inoculum on Lowenstein-Jensen medium containing Md (or Pz) at concentrations higher than their respective minimum inhibitory concentrations (MICs). These were then tested to find out if such mutants have changed their resistogramme pattern with respect to the test antitubercular agents. Certain first-step Md-mutants became simultaneously resistant to ethambutol and pyrazinamide; while the step-2 Md-mutants revealed further increase in resistance to these agents along with resistance to isoniazid, rifampicin and streptomycin as well. In the study with Pz it was noted that many mutants showed distinctly higher levels of resistance to all the test drugs, particularly to isoniazid, pyrazinamide and streptomycin. The levels of MIC were distinctly high in many mutants. These observations on cross-resistances seem to be best explained on the basis of a reduction in cell-membrane permeability acting in a non-specific manner. The role of such a cross-resistance may possibly be accounting for an overall increase in the MICs of many drugs against several groups of microorganisms including Mycobacterium tuberculosis and other species of Mycobacterium during the last five decades.
机译:在过去的几十年中,已发现几种针对人类不同疾病的化学治疗剂具有有效的抗结核活性。使用了两种这样的试剂,甲苯哒嗪(Md)和异丙嗪(Pz)来选择以不同水平对其自身具有抗性的分枝杆菌突变体,并进行测试以确定这些突变体是否同时对已知的抗结核药物产生交叉耐药性。突变体是通过在含有Md(或Pz)的Lowenstein-Jensen培养基上重接种以高于其最低抑菌浓度(MIC)的浓度产生的。然后对它们进行测试,以查明这些突变体相对于测试抗结核药是否改变了它们的抗蚀图模式。某些第一步的Md突变体同时具有对乙胺丁醇和吡嗪酰胺的抗性。而第2步的Md突变体显示出对这些药物的抵抗力进一步增强,以及对异烟肼,利福平和链霉素的抵抗力。在对Pz的研究中,注意到许多突变体对所有受试药物,特别是对异烟肼,吡嗪酰胺和链霉素的耐药性明显更高。在许多突变体中,MIC的水平明显较高。这些关于交叉电阻的观察似乎最好是以非特异性方式降低细胞膜通透性的基础来解释。在过去的五十年中,这种交叉耐药的作用可能解释了许多药物对包括结核分枝杆菌和其他分枝杆菌在内的几类微生物的MIC总体增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号